291 studies found for:
"primary pulmonary hypertension"
| Rank | Status | Study | ||||
|---|---|---|---|---|---|---|
| 1 | Recruiting |
Efficacy Study of Cardizem in Pulmonary Arterial Hypertension
|
||||
| 2 | Withdrawn |
Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder
|
||||
| 3 | Unknown † |
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
|
||||
| 4 | Completed |
Imatinib (QTI571) in Pulmonary Arterial Hypertension
|
||||
| 5 | Completed |
Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)
|
||||
| 6 | Recruiting |
Coenzyme Q-10 and Pulmonary Arterial Hypertension
|
||||
| 7 | Recruiting |
Pharmacogenomics in Pulmonary Arterial Hypertension
|
||||
| 8 | Recruiting |
Auto-immunity and Pulmonary Arterial Hypertension
|
||||
| 9 | Completed |
Responsiveness of Exercise Tests in Pulmonary Arterial Hypertension
|
||||
| 10 | Unknown † |
Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension
|
||||
| 11 | Completed |
The Early Recognition of Pulmonary Arterial Hypertension
|
||||
| 12 | Not yet recruiting |
Patient Reported Outcomes in Pulmonary Arterial Hypertension
|
||||
| 13 | Recruiting |
Endothelial Function in Patients With Pulmonary Arterial Hypertension
|
||||
| 14 | Withdrawn |
Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension
|
||||
| 15 | Recruiting |
Peripheral Muscle Microcirculation and Exercise-induced Blood Flow Distribution in Pulmonary Arterial Hypertension
|
||||
| 16 | Enrolling by invitation |
ACT-293987 in Pulmonary Arterial Hypertension
|
||||
| 17 | Not yet recruiting |
Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension
|
||||
| 18 |
Completed
Has Results |
Iloprost Power 15 in Pulmonary Arterial Hypertension
|
||||
| 19 | Active, not recruiting |
Pulmonary Arterial Hypertension in Children
|
||||
| 20 | Recruiting |
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
|
† Indicates status has not been verified in more than two years
